STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] TScan Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, report beneficial ownership of 1,350,000 shares of TScan Therapeutics Voting Common Stock issuable upon exercise of warrants. These shares represent 2.52% of the company's Voting Common Stock based on an aggregate of 52,314,039 shares outstanding used for the calculation. The filing shows shared voting and dispositive power over the 1,350,000 warrant‑issued shares and no sole voting or dispositive power.

This position is reported as holdings through Adage affiliates and reflects potential future dilution if the warrants are exercised; the reported amount is not currently held as sole-owned shares.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Adage discloses a modest 2.52% position via warrants—potential dilution but not a controlling stake.

The report discloses 1,350,000 shares issuable upon exercise of warrants held through Adage affiliates, producing a 2.52% stake on the stated share base of 52,314,039. Because the position is below 5% and recorded as shared voting/dispositive power, this is a routine disclosure signaling potential dilution rather than an active control initiative. Investors should note the holdings are derivative in nature (warrants), so immediate voting influence and economic exposure differ from outright share ownership.

TL;DR: Shared voting power over warrant‑issued shares indicates coordination but does not imply control.

The filing identifies Adage and two named principals with shared voting and dispositive authority over the 1.35M warrant‑linked shares. Reporting as shared power and classification as investment adviser/parent entities suggests governance involvement through standard investment structures rather than an intent to change control. The position size (2.52%) is below conventional thresholds that typically trigger more substantive governance concerns or mandatory tender/merger notifications.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The 1,350,000 shares of Voting Common Stock (as defined in Item 2(a)) reported herein are issuable upon exercise of warrants.


SCHEDULE 13G




Comment for Type of Reporting Person: The 1,350,000 shares of Voting Common Stock reported herein are issuable upon exercise of warrants.


SCHEDULE 13G




Comment for Type of Reporting Person: The 1,350,000 shares of Voting Common Stock reported herein are issuable upon exercise of warrants.


SCHEDULE 13G



Adage Capital Management, L.P.
Signature:/s/ Robert Atchinson
Name/Title:By: Adage Capital Partners LLC, its General Partner, By: Robert Atchinson, its Managing Member
Date:08/12/2025
Robert Atchinson
Signature:/s/ Robert Atchinson
Name/Title:Robert Atchinson, individually
Date:08/12/2025
Phillip Gross
Signature:/s/ Phillip Gross
Name/Title:Phillip Gross, individually
Date:08/12/2025

FAQ

What did Adage report for TCRX?

Adage Capital, Robert Atchinson and Phillip Gross reported beneficial ownership of 1,350,000 TCRX shares issuable upon exercise of warrants.

What percentage of TCRX does the reported position represent?

The reported amount represents 2.52% of TScan Therapeutics' Voting Common Stock based on 52,314,039 shares used in the calculation.

Are the reported TCRX shares currently outstanding or issuable upon exercise?

The 1,350,000 shares are issuable upon exercise of warrants, not described as presently held common shares.

Do the reporting persons have sole voting or dispositive power over these TCRX shares?

No. The filing shows 0 sole voting power and 1,350,000 shared voting and shared dispositive power for each reporting person.

Through what entity are the warrants held?

The warrants are directly held by Adage Capital Partners, L.P. (ACP), with Adage Capital Management, L.P. acting as investment manager.
Tscan Therapeutics, Inc.

NASDAQ:TCRX

TCRX Rankings

TCRX Latest News

TCRX Latest SEC Filings

TCRX Stock Data

105.55M
52.27M
0.23%
79.47%
3.02%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
WALTHAM